In the past, large phase III trials have failed at great expense and there are still many possible combination regimens to be evaluated in phase III. Furthermore, there is increasing evidence that culture conversion during treatment, however measured, has a limited role in decision-making for advancing regimens into phase III trials. The innovative multi arm,…
PanACEA has a strong history of well conducted clinical trials to evaluate new regimens for the treatment of drug sensitive TB. Our studies range from small two-center early Phase IIA studies through to large-scale Phase III studies in a multitude of sites and countries. At the start of the consortium, separate development programmes were conducted…
Accelerating the pathway from drug discovery to patient treatment – pioneering advanced development methodologies for new TB drug regimens.
